학술논문
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
Document Type
Article
Author
Hillus, David; Schwarz, Tatjana; Tober-Lau, Pinkus; Vanshylla, Kanika; Hastor, Hana; Thibeault, Charlotte; Jentzsch, Stefanie; Helbig, Elisa T; Lippert, Lena J; Tscheak, Patricia; Schmidt, Marie Luisa; Riege, Johanna; Solarek, André; von Kalle, Christof; Dang-Heine, Chantip; Gruell, Henning; Kopankiewicz, Piotr; Suttorp, Norbert; Drosten, Christian; Bias, Harald; Seybold, Joachim; Al-Rim, Ben; Bardtke, Lara; Beheim-Schwarzbach, Jörn Ilmo; Behn, Kerstin; Bergfeld, Leon; Bethke, Norma; Bleicker, Tobias; Briesemeister, Dana; Brumhard, Sophia; Conrad, Claudia; Dieckmann, Sebastian; Frey, Doris; Gabelich, Julie-Anne; Georg, Philipp; Gläser, Ute; Hasler, Lisbeth; Hetey, Andreas; Hiller, Anna Luisa; Horn, Alexandra; Hülso, Claudia; Kegel, Luisa; Koch, Willi; Krannich, Alexander; Kroneberg, Paolo; Lisy, Michelle; Mackeldanz, Petra; Maeß, Birgit; Münn, Friederike; Olk, Nadine; Peiser, Christian; Pohl, Kai; Hermel, Annelie; Rönnefarth, Maria; Rubisch, Carolin; Sanchez Rezza, Angela; Schellenberger, Isabelle; Schenkel, Viktoria; Schlesinger, Jenny; Schmidt, Sein; Schwanitz, Georg; Sinnigen, Anne-Sophie; Stubbemann, Paula; Tesch, Julia; Treue, Denise; Wendisch, Daniel; Zvorc, Saskia; Klein, Florian; Kurth, Florian; Corman, Victor Max; Sander, Leif Erik
Source
The Lancet Respiratory Medicine; November 2021, Vol. 9 Issue: 11 p1255-1265, 11p
Subject
Language
ISSN
22132600; 22132619
Abstract
Heterologous vaccine regimens have been widely discussed as a way to mitigate intermittent supply shortages and to improve immunogenicity and safety of COVID-19 vaccines. We aimed to assess the reactogenicity and immunogenicity of heterologous immunisations with ChAdOx1 nCov-19 (AstraZeneca, Cambridge, UK) and BNT162b2 (Pfizer-BioNtech, Mainz, Germany) compared with homologous BNT162b2 and ChAdOx1 nCov-19 immunisation.